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Introduction
Mutations in BRCA1 and BRCA2 are associated with a
high risk of developing cancer of the breast, of the ovaries
and of other organs [1]. A large number of cancer-
associated mutations in these genes have been described
to date; however, few studies have directly probed the
functional consequences of individual mutations [2–5].
One question that has thus rarely been addressed is
whether the increased risk of cancer is simply due to the
lack of one healthy copy of the gene (haploinsufficiency)
or whether the gene produces a protein product that
interferes with normal cellular processes.
Most nonsense (insertion/deletion) mutants are thought to
result in unstable transcripts and in little or no mutant
protein production [6]. Exceptions to this rule are found,
however, also among the BRCA genes where proteins
encoded by the following mutant genes have been
detected: BRCA1 5382insC (Breast Cancer Consortium)
and BRCA2 6174delT [2]. Perhaps the most intriguing
evidence for a potential functional role for truncated
BRCA2 mutants comes from the observation that cancer
risk is affected by the location of the mutation. Mutations
in a central portion of BRCA2, commonly termed the
ovarian cancer cluster region, are thus associated with
bp = base pairs; DMEM = Dulbecco’s modified Eagle’s medium; ELISA = enzyme-linked immunosorbent assay; FCS = fetal calf serum; wt = wild
type.
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Abstract
Introduction: A founder mutation in the BRCA2 gene (BRCA2
999del5) accounts for 7–8% of female breast cancers and for
40% of male breast cancers in Iceland. If expressed, the
mutant gene would encode a protein consisting of the first 256
amino acids of the BRCA2 protein. The purpose of this study
was to determine whether this mutant protein is produced in
heterozygous individuals and, if so, what might be the
functional consequences of mutant protein production.
Methods: The presence of BRCA2 999del5 transcripts in
fibroblasts from heterozygous individuals was assayed by
cDNA synthesis and sequencing. The potential protein-coding
portion of BRCA2 999del5 was cloned into the pIND(SP1)/
V5-His vector and expressed in COS7 cells. The presence of
the mutant protein in cell lysates from heterozygous fibroblasts
and from COS7 cells was tested by a number of methods
including immunoprecipitation, affinity purification with nickel-
coated agarose beads, Western blotting and ELISA, using
antibodies to the N-terminal end of BRCA2, antiserum specific
for the 16 nonrelevant amino acids at the carboxyl end and
antibodies to fusion partners of recombinant proteins.
Results: The frequency of the BRCA2 999del5 transcript in
heterozygous fibroblasts was about one-fifth of the wild-type
transcript; however, no mutant protein could be detected.
Overexpression of BRCA2 999del5 mRNA in COS7 cells
failed to produce a mutant protein unless degradation by
proteasomes was blocked.
Conclusion: Our results show that the protein product of
BRCA2 999del5 is extremely unstable. Therefore, an increase
in breast cancer risk in BRCA2 999del5 carriers is due to
haploinsufficiency at the BRCA2 locus.
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significantly higher risk of ovarian cancer but with lower
risk of breast cancer than mutations in other regions of
BRCA2 [7,8]. This variation in cancer risk is difficult to
explain without invoking some effect of a protein
product.
A single BRCA2 mutation accounts for 7–8% of breast
cancers in Iceland [9]. The Icelandic mutation, a 5 bp
deletion in exon 9 starting at nucleotide 999 (BRCA2
999del5), leads to a stop codon at nucleotide 1047 and
to premature truncation of protein translation [10,11]. The
truncated mutant protein is predicted to have the first 256
amino acids of wild-type (wt) BRCA2, followed by 16 out-
of-frame amino acids, and an estimated mass of about
35 kDa. The fact that BRCA2 999del5 represents the
only known founder mutation in Iceland has set the stage
for extensive population-based genetic and epidemio-
logical studies on the effect of this mutation [9,12,13].
However, to date, no information has been collected on
the potential expression of the BRCA2 999del5 gene in
heterozygous individuals.
The aim of the present study was to analyze expression of
the mutated BRCA2 gene in BRCA2 999del5 hetero-
zygous cells to determine the functional consequences of
BRCA2 999del5 at the cellular level.
Materials and methods
Cells and cell lines
Fibroblasts from individuals heterozygous for BRCA2
999del5 were grown in RPMI 1640 (Invitrogen Life
Technologies, Carlsbad, CA, USA) supplemented with
20% FCS, 100 U/ml penicillin and 100 µg/ml
streptomycin. Overexpressions were performed in COS7
cells (ATCC, Rockville, MD, USA) grown in DMEM
(Invitrogen Life Technologies) supplemented with 10%
FCS, 100 U/ml penicillin and 100 µg/ml streptomycin.
RNA isolation, cDNA synthesis and cloning of BRCA2
999del5
Total RNA was isolated using the TRIZOL Reagent
(Invitrogen Life Technologies). Three micrograms of total
RNA were used for cDNA synthesis (First-Strand cDNA
Synthesis kit; Amersham Biosciences, Hilleröd, Denmark).
The open reading frame of BRCA2 999del5 was
amplified using a primer pair where the 5′ primer was
complementary to the Kozak sequence of the BRCA2
cDNA and the 3′ primer covered a 22 bp region prior to
the putative stop codon of the BRCA2 999del5 cDNA.
The sequences were GTAAAAATGCCTATTGGATCC for
the 5′ cloning primer, and AATGAATTCCCTGATGTT-
TTTC for the 3′cloning primer.
The reaction mixture contained 2 µl cDNA template, 2 mM
MgCl2, 15 nmol dNTPs, 15 pmol each primer and 2 U Taq
polymerase. The reaction proceeded at 95°C for 5 min,
followed by 40 cycles of 94°C for 1 min, 55°C for 45 s
and 72°C for 1 min, and finally heating to 72°C for 5 min
and cooling to 4°C.
The amplified BRCA2 product was isolated by electro-
phoresis on a 1% agarose gel, and then the DNA purified
(GFX PCR DNA and Gel Band Purification Kit; Amersham
Biosciences), cloned into pCR2.1-TOPO vector
(Invitrogen Life Technologies) and used to transform
TOP10 bacteria. Plasmids were purified from individual
bacterial clones (Qiagen Plasmid purification Kit; Qiagen
GmbH, Hilden, Germany) and the clones were sequenced
(ABI PRIZM Big Dye Terminator Cycle Sequencing Ready
Reaction kit; Applied Biosystems, Foster City, CA, USA).
After the deletion had been confirmed, the mutated DNA
insert was excised from the TOPO-TA plasmid with HindIII
and  NotI restriction enzymes (New England Biolabs,
Beverly, MA, USA) and ligated into the pIND(SP1)/V5-His
expression vector (Invitrogen Life Technologies).
Transfections and activation of expression
Cells were grown to 60–65% confluency. Four microliters
of FuGENE 6 reagent (Roche Applied Science, Hvidovre,
Denmark) were added to 250 µl serum-free medium and
the mixture was incubated for 5 min at room temperature.
After the addition of plasmid DNA (2 µg per transfection),
the mixture was incubated for 20 min at room temperature
and then added to the cell cultures that had received fresh
serum-containing medium. The cell cultures were allowed
to recover after transfection for 24 hours, fresh medium was
added and the cells were subsequently activated with ponas-
terone A (Invitrogen Life Technologies) at a concentration
of 2.5 µg/ml, as recommended by the manufacturer.
Cell lysis, precipitations, and Western blotting
Cells were lysed in RIPA lysis buffer containing 1% Triton
X-100, 1% deoxycholic acid, 20 mM Tris–HCl (pH 7.4),
150 mM NaCl, 2.5 mM EDTA, 10% glycerol and 10 mM
Na3P2O7, as well as 160 inhibitory units/ml aprotinin and
0.5 mM phenylmethylsulfonyl fluoride. After lysis, 10% of
the lysate was removed (for use as a control) and the rest
was incubated with antibody. For immunoprecipitations,
2.5 µl primary monoclonal antibody or 5 µl primary
polyclonal antibody were used per precipitation. After the
addition of antibody, the samples were subjected to gentle
end-over-end shaking for 1–2 hours at 4°C. Subsequently,
50 µl Protein G Sepharose beads (Amersham
Biosciences) were added to each sample and the mixture
incubated for a further 1 hour at 4°C. The beads were
washed with lysis buffer, the supernate was removed and
50 µl of 2 × sample buffer containing β-mercaptoethanol
were added to the beads. The samples were boiled for
5 min and were centrifuged for 30 s.
For precipitation of the overexpressed 6×His-tagged
proteins, Ni-NTA Magnetic Agarose Beads (QiagenBreast Cancer Research    Vol 6 No 4 Mikaelsdottir et al.
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GmbH) were used. For purification of the 6×His-tagged
proteins under native conditions, cells transiently
transfected with pIND-BRCA2 999del5 or with pIND-
LacZ were lysed in lysis buffer containing 50 mM
NaH2PO4 (pH 8), 300 mM NaCl, 10 mM imidazole, 1%
Tween 20. Ten microliters of 5% Ni-NTA Magnetic
Agarose Bead suspension were added to the lysate and
incubated for 1–2 hours at 4°C. The supernate was
separated from the beads using a Qiagen 12-Tube
Magnet (Qiagen) and the beads were washed several
times with washing buffer containing 50 mM NaH2PO4
(pH 8), 300 mM NaCl, 20 mM imidazole, 0.05% Tween
20. The proteins were eluted from the beads with 25 µl
elution buffer containing 50 mM NaH2PO4 (pH 8), 300 mM
NaCl, 250 mM imidazole, 0.05% Tween 20, an equal
volume of 2 x sample buffer supplemented with β-
mercaptoethanol was added to the eluates, and the
samples were boiled for 5 min and centrifuged for 30 s.
Purification of the 6×His-tagged proteins under denaturing
conditions proceeded in exactly the same way except that
the cells were lysed in a buffer containing 8 M urea, 0.1 M
NaH2PO4, 0.01 M Tris–Cl (pH 8), that the agarose beads
with the bound 6×His-tagged proteins were washed with a
buffer containing 8 M urea, 0.1 M NaH2PO4, 0.01 M
Tris–Cl (pH 6.3), and that a buffer containing 8 M urea,
0.1 M NaH2PO4, 0.01 M Tris–Cl (pH 4.5) was used for
elution of the proteins from the beads.
The precipitates and the lysates were separated by
electrophoresis on gradient 6–18% polyacrylamide gels
and blotted onto a Hybond-P membrane (Amersham
Biosciences). The primary antibodies used in this study
were: SC1 and SC3 rat monoclonal antibodies raised
against the N-terminal and C-terminal sequences of
BRCA2, respectively (a generous gift from D Bertwistle
and A Ashworth); anti-V5 mouse monoclonal antibody
(Invitrogen Life Technologies); anti-actin mouse
monoclonal antibody (SDS); anti-BRCA2 rabbit polyclonal
antibody raised against the putative out-of-frame residues
at the C-terminus of BRCA2 999del5 (Bethyl
Laboratories, Montgomery, TX, USA); and NCL-p53-DO7
mouse monoclonal antibody against p53 (Novocastra,
Newcastle, UK). Secondary peroxidase-conjugated
donkey anti-mouse and donkey anti-rabbit horseradish
antibodies were purchased from Amersham Biosciences
and peroxidase-conjugated goat anti-rat antibody was
purchased from Pierce Biotechnology (Rockford, IL, USA).
The ECL detection system (Amersham Biosciences) was
used to produce images.
Northern blotting
Total RNA samples (about 15 µg each) were separated
by electrophoresis on a 1% agarose gel containing 2.2 M
formaldehyde and 0.02 M 3-(N-morpholino)propane-
sulfonic acid, stained with ethidium bromide and
visualized by UV. The gels were blotted onto Hybond-N+
membrane (Amersham Biosciences) and RNA was
subsequently fixed by exposing the membrane to UV light
for 5 min. The BRCA2 999del5 insert of the pIND-
BRCA2 999del5 plasmid was excised from the vector
with HindIII and NotI. Then 100 ng insert were labeled
using the ECL direct nucleic acid labeling system
(Amersham Biosciences) and were used as a probe. The
labeled probe was added to a hybridization buffer
containing 0.5 M NaCl and 5% blocking agent, and the
mixture was incubated with the membrane overnight at
42°C. The images were developed using the ECL
detection system (Amersham Biosciences).
ELISA
F96 Maxisorp immunoplates from Nunc (Roskilde,
Denmark) were coated with cell lysates. The synthetic 16
amino acid peptide alone (the predicted 16 out-of-frame
amino acid stretch of BRCA2 999del5), and the same
peptide conjugated to keyhole limpet hemocyanin carrier
protein were used as controls. Briefly, wells were coated
with different dilutions (1:10, 1:100, 1:1000) of lysates
prepared from the heterozygous fibroblasts on one hand,
and from homozygous wt fibroblasts on the other hand, all
made in duplicate. About 250 ng synthetic peptides were
used to coat each control well. All the samples were
diluted in coating buffer containing 0.015 M Na2CO3,
0.035 M NaHCO3, and 0.003 M NaN3 (pH 9.6), which
was also used as a blank. The same experiment was
performed with the lysates of the COS7 cells transfected
with pIND-BRCA2 999del5 or with pIND-LacZ as control.
The antibody against the putative 16 out-of-frame amino
acid stretch of BRCA2 999del5 (dilution 1:2500) was
used to detect the presence of the mutated BRCA2
protein. Preimmune serum was used as a control. The
secondary antibody used was goat anti-rabbit alkaline
phosphatase-conjugated antibody (DAKOCytomation,
Glostrup, Denmark) diluted 1:3000 in PBS–0.05%
Tween 20.
Proteasome inhibition
To investigate whether the proteasome plays a role in the
instability of BRCA2 999del5 protein, the proteasome
inhibitor lactacystin was used to treat cells overexpressing
pIND-BRCA2 999del5 or pIND-LacZ. Briefly, 24 hours
after transfection, the cells were treated with ponasterone
A and consequently with lactacystin at a concentration of
10 µM for different periods of time. The cells were
thereafter lysed and subjected to electrophoresis on
gradient 6–18% polyacrylamide gel, transferred onto
Hybond-P membrane and blotted with α-V5 or with the
antibody against the nonrelevant residues of BRCA2
999del5 or SC1 antibody. Blotting with α-actin was
performed as a control for protein loading, and blotting
with α-p53 was performed as a control for proteasome
inhibition.Results
Expression of BRCA2 999del5 mRNA in heterozygous
cells
We tested whether mRNA encoding the mutated copy of
the  BRCA2 gene was present in cells heterozygous for
BRCA2 999del5. cDNA was prepared from heterozygous
fibroblasts, and an 822 bp region, covering the open
reading frame of BRCA2 999del5, was amplified and
cloned into TOPO plasmid. Sequencing of individual cDNA
clones confirmed the existence of the mutant transcript.
Out of 24 randomly chosen clones, five (approximately
20%) had the 5 bp deletion. Thus, although the mutant
gene is transcribed, it is probable that the resulting mRNA
is less stable than the mRNA transcript of the wt gene.
No BRCA2 999del5 mutant protein could be detected in
heterozygous cells
The existence of mutated protein in fibroblasts hetero-
zygous for BRCA2 999del5 was investigated by Western
blotting. Two different antibodies were used for detection
of the mutated protein: rat monoclonal antibody raised
against amino acids 5–19 of human BRCA2 (SC1), and
rabbit antiserum raised against the predicted 16 out-of-
frame amino acid stretch of BRCA2 999del5. Rat
monoclonal antibody raised against amino acids
3386–3400 of human BRCA2 (SC3) and the SC1
antibody were used to detect wt BRCA2. There was no
difference in the banding pattern of lysates of hetero-
zygous samples compared with lysates with wt BRCA2
for any of these antibodies (data not shown). Immuno-
precipitations with the SC1 antibody also failed to detect
any mutant protein.
Overexpression of BRCA2 999del5 in COS7 cells
The inability to detect mutant proteins in BRCA2 999del5
heterozygous cells by Western blotting could be due to
the lack of sensitivity of the antibody reagents. To test this
possibility, the open reading frame of BRCA2 999del5
was cloned into the pIND(SP1)/V5-His vector. COS7
cells were transfected with pIND-BRCA2 999del5 and
pVgRXR (Ecdysone-receptor plasmid), and 24 hours later
expression of pIND-BRCA2 999del5 was induced by
ponasterone A. Parallel transfections with pIND-LacZ
plasmid were used as positive control. Northern blot analysis
showed that BRCA2 999del5 RNA was expressed at
high levels in transfected cells (Fig. 1). As the pIND
plasmid contains sequences encoding a V5 epitope and a
6×His tag (poly-His), the cell lysates were probed for
recombinant protein by affinity purification with either anti-
V5 antibody or Ni-NTA magnetic agarose beads. No
overexpressed BRCA2 999del5 protein could be
detected either in total cell lysates (Fig. 2a) or after
purification on nickel-coated beads or precipitation with α-
V5 (Figs 2b and 2c, respectively). Thus, despite efficient
transcription of the plasmids and clear detection of the
LacZ protein, no mutant BRCA2 protein could be found.
ELISA fails to detect both endogenous and
overexpressed mutant protein
BRCA2 has proven to be a poor antigen for antibody
production, hampering studies on the functional aspects
of the protein. To try to gain a better handle on the
BRCA2 999del5 protein product, a rabbit antiserum
directed at the 16 out-of-frame amino acids of the putative
protein was produced. An ELISA assay was used to try to
detect mutant BRCA2 protein, employing this antiserum.
In the first set of experiments, wells were coated with
lysates of heterozygous fibroblasts on one hand, and with
lysates of wt fibroblasts on the other. The synthetic peptide
used for antibody generation was used as a control. As
shown in Fig. 3a, no mutant protein was detected in this
assay. Furthermore, when lysates of cells transfected with
pIND-BRCA2 999del5 were tested in the same assay,
they also failed to detect any mutant protein (Fig. 3b).
Detection of BRCA2 999del5 protein after proteasome
inhibition
After all the different attempts to detect the mutant
BRCA2 protein had failed, we had still not been able to
demonstrate whether this was due to extremely rapid
degradation of the protein or simply to a lack of sensitivity
by our detection methods. To try to distinguish between
these possibilities, we performed proteasome inhibitions
of COS7 cells overexpressing BRCA2 999del5.
In the first set of proteasome inhibition experiments, the
cells were inhibited for 0, 5, 10 and 20 hours, and cell
lysis and protein purification were performed under non-
denaturing conditions. Western blotting of p53 was used
as a control for successful inhibition. No mutant BRCA2
protein was detectable in these samples (data not shown).
Available online http://breast-cancer-research.com/content/6/4/R284
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Figure 1
Overexpression of BRCA2 999del5 mRNA in COS7 cells. The
potential coding sequence of BRCA2 999del5 was cloned into the
pIND(SP1)/V5-His expression vector, transfected into COS7 cells and
induced with ponasterone A: 1, mock transfection; 2, cells transfected
with pIND-BRCA2 999del5; and 3, untransfected COS7 cells. (a)
Expression of BRCA2 999del5 was confirmed by northern blotting
with a labeled BRCA2 999del5 probe. (b) RNA samples that were
used in northern blotting stained with ethidium bromide and visualized
with UV light.There is a possibility that the protein is missing from the
lysate because the recombinant protein is folded in such
a way that the V5 epitope and the poly-His tag are
inaccessible to the α-V5 antibody and nickel-coated
agarose beads, respectively. Therefore, in a new set of
experiments, the cells were lysed and the proteins
purified under denaturing conditions. No protein could
be detected in the lysates or after purification with nickel
when the cells were not treated with proteasome
inhibitors (Fig. 4a). However, when the cells had been
treated with lactacystin for 5 hours, a 39 kDa band (the
expected size of recombinant BRCA2 999del5)
emerged and showed a definite increase after 10 hours
(Fig. 4b). These results show that even when
overexpressed, the BRCA2 999del5 protein is rapidly
degraded. It is therefore highly unlikely that this mutant
protein has any functional effect in heterozygous
individuals.
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Figure 2
No mutant BRCA2 protein was detected in overexpression experiments. (a) Lysates of transfected COS7 cells were subjected to electrophoresis
through 6–18% gradient gel and blotted with an antibody against the V5 tag (α-V5): 1, untransfected cells; 2, pIND-LacZ transfected cells; 3, cells
cotransfected with both pIND-LacZ and pIND-BRCA2 999del5; and 4, cells transfected with pIND-BRCA2 999del5. (b) Nickel-coated agarose
beads were used to adsorb recombinant proteins under native conditions. The proteins were subjected to electrophoresis through 6–18% gradient
gel and blotted with α-V5: 1, untransfected COS7 cells; 2, cells overexpressing pIND-BRCA2 999del5; and 3, cells overexpressing pIND-LacZ.
(c) α-V5 was used to precipitate recombinant proteins and for immunoblotting: 1, untransfected COS7 cells; 2, cells transfected with pIND-LacZ;
3, cells transfected with pIND-BRCA2 999del5 without induction; and 4, cells transfected with pIND-BRCA2 999del5 with induction.
Figure 3
No mutant protein could be detected by ELISA. (a) Lysates of fibroblasts with wild-type BRCA2 (wt) and fibroblasts heterozygous for BRCA2
999del5 (Mut) were tested for the presence of BRCA2 999del5 protein: bar pairs 3 and 4, lysates diluted 1:10; bar pairs 5 and 6, lysates diluted
1:100; bar pairs 7 and 8, lysates diluted 1:1000. (b) The same experiment was performed using lysates from untransfected COS7 cells (COS7),
and COS7 cells overexpressing pIND-LacZ (Mock) or pIND-BRCA2 999del5 (Mut): bar pairs 3, 4 and 5, lysates diluted 1:10; bar pairs 6, 7 and 8,
lysates diluted 1:100; bar pairs 9, 10 and 11, lysates diluted 1:1000. The synthetic peptide, representing the 16 out-of-frame amino acids (a.a.) of
BRCA2 999del5 and used to raise the antiserum, was used as a positive control.Discussion
A large number of mutations in the BRCA2 gene have
been identified to date that predispose to breast cancer,
as well as to cancers in other organs. However, relatively
few functional studies have been carried out on mutant
BRCA2 proteins.
In the case of truncating mutations, it is often assumed
that these alleles give rise to unstable transcripts that are
detected and eliminated by a nonsense-mediated mRNA
decay pathway [14,15]. In the cases where residual
nonsense transcripts escape this elimination process, they
may not be available to the translation machinery because
they are not trafficked to the cytoplasm or may not be
properly assembled into a closed loop conformation,
precluding efficient translation initiation [6]. As a result, it
has been generally accepted that most truncation mutants
of the BRCA genes lead to haploinsufficiency.
It should be noted, however, that this rule is not universal
and that mutant BRCA gene products have been detected
in at least two cases: BRCA1 5382insC, which is located
in exon 20 of BRCA1, altering the reading frame after
codon 1755 and terminating translation at codon 1829
[16] (our own investigation of the HCC1937 breast
cancer cell line); and BRCA2 6174delT, which is located
in exon 11, causing protein truncation after codon 2002,
and is detected by Western blotting as a protein of about
250 kDa in the CAPAN-1 pancreatic cancer cell line [2].
In addition, indirect evidence suggests that in some cases
mutant BRCA protein products may affect the oncogenic
process. First, it has been firmly demonstrated that
mutations in a 3.3 kb region in exon 11, termed the ovarian
cancer cluster region, are preferentially associated with
ovarian cancer rather than with breast cancer [7,17]. The
mechanism underlying this difference in phenotype is not
understood, but the observation that this region coincides
with the RAD51-binding domain of BRCA2 [18,19]
suggests that mutant proteins might be involved. Second,
a few studies have examined the functional effect of
overexpression of truncated BRCA gene products. It was
thus shown that several carboxyl-terminal truncated
BRCA1 proteins conferred decreased susceptibility to
apoptosis, impaired ability to suppress tumor growth in
vivo and blocked the function of ectopically expressed
BRCA1 [3]. Furthermore, a truncated BRCA1 mutant led
to dominant negative effect of BRCA1, as shown by an
increase in both tumorigenicity in vivo and chemo-
sensitivity [5]. Taken together, these observations suggest
that it may be necessary to study each mutation separately
at the cellular level.
In the present study, we examined mRNA and protein
expression of a BRCA2 gene carrying an Icelandic
founder mutation. Mutant mRNA represented about 20%
of the total BRCA2  transcript, demonstrating that the
mutant message is present but is probably less stable
than its normal counterpart. Notably, we were unable to
find any traces of mutant protein product although several
different techniques were employed.
Because negative results always leave open the possibility
that the detection methods have failed, we went to
considerable lengths in trying to overexpress mutant
BRCA 999del5 protein in COS7 cells. BRCA2 999del5
is predicted to contain the first 256 amino acids of wt
BRCA2 followed by 16 out-of-frame amino acids, and to
have a mass of around 35 kDa. This means that although
the putative protein lacks the nuclear localization signal
found at the carboxyl terminus of the protein [2], it would
probably be able to diffuse passively into the nucleus
because the cutoff mass for passive diffusion through the
nuclear pore is 65 kDa [20,21]. This possibility sets
BRCA2 999del5 apart from larger known BRCA2
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Figure 4
Detection of BRCA2 999del5 protein under denaturing conditions and
after proteasome inhibition. (a) COS7 cells were transfected with
pIND-BRCA2 999del5 or pIND-LacZ without proteasome inhibition.
Samples were treated under denaturing conditions. (b) COS7 cells
were transfected with pIND-BRCA2 999del5 or pIND-LacZ with
proteasome inhibition. Samples were purified with nickel-coated
agarose beads under denaturing conditions. Samples in both (a) and
(b) were blotted with an antibody against the V5 tag (α-V5).mutants, which are kept in the cytoplasm due to the lack
of nuclear localization signal.
We searched for the BRCA2 999del5 protein both in the
cytoplasm and in the nucleus, but to no avail. Our results
demonstrate that the BRCA2 999del5 encoded protein is
extremely unstable and not detectable in cell lysates
except under conditions that block degradation by protea-
somes. This extreme instability of the protein makes it
highly unlikely that it has any functional effect in hetero-
zygous cells and supports strongly the fact that the
increased cancer risk of BRCA2 999del5 carriers is solely
due to haploinsufficiency.
Conclusions
In the present study, we asked whether the increased risk
of cancer in BRCA2 999del5 carriers is simply due to
haploinsufficiency or whether the gene produces a protein
product that interferes with normal cellular processes.
Although  BRCA2 999del5 mRNA was detected in
heterozygous cells, we found no evidence of mutant
protein in cell lysates. Furthermore, overexpression studies
showed that the BRCA2 999del5 protein is extremely
unstable.  BRCA2 999del5-associated cancer risk is
therefore most probably due to haploinsufficiency.
Competing interests
None declared.
Acknowledgements
This study was supported by grants from the Icelandic Research
Council and from the Icelandic Cancer Society.
References
1. Welcsh PL, King MC: BRCA1 and BRCA2 and the genetics of
breast and ovarian cancer. Hum Mol Genet 2001, 10:705-713.
2. Spain BH, Larson CJ, Shihabuddin LS, Gage FH, Verma IM: Trun-
cated BRCA2 is cytoplasmic: implications for cancer-linked
mutations. Proc Natl Acad Sci USA 1999, 96:13920-13925.
3. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM: Mutant
BRCA1 genes antagonize phenotype of wild-type BRCA1.
Oncogene 2001, 20:8215-8235.
4. Brown MA, Nicolai H, Howe K, Katagiri T, Lalani el-N, Simpson KJ,
Manning NW, Deans A, Chen P, Khanna KK, Wati MR, Griffiths
BL, Xu CF, Stamp GW, Solomon E: Expression of a truncated
Brca1 protein delays lactational mammary development in
transgenic mice. Transgenic Res 2002, 11:467-478.
5. Sylvain V, Lafarge S, Bignon YJ: Dominant-negative activity of a
Brca1 truncation mutant: effects on proliferation, tumorigenic-
ity in vivo, and chemosensitivity in a mouse ovarian cancer
cell line. Int J Oncol 2002, 20:845-853.
6. Mendell JT, Dietz HC: When the message goes awry: disease-
producing mutations that influence mRNA content and perfor-
mance. Cell 2001, 107:411-414.
7. Thompson D, Easton D: Variation in cancer risks, by mutation
position, in BRCA2 mutation carriers. Am J Hum Genet 2001,
68:410-419.
8. Consortium SNIBB: BRCA1 and BRCA2 mutations in Scotland
and Northern Ireland. Br J Cancer 2003, 88:1256-1262.
9. Tulinius H, Olafsdottir GH, Sigvaldason H, Arason A, Barkardottir
RB, Egilsson V, Ogmundsdottir HM, Tryggvadottir L, Gudlaugs-
dottir S, Eyfjord JE: The effect of a single BRCA2 mutation on
cancer in Iceland. J Med Genet 2002, 39:457-462.
10. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D,
Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet
D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T,
Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P,
Kehrer R, Leblanc J-F, Mitchell JT, McArthur-Morrison J, Nguyen K,
Peng Y, Samson C, Schroeder M, Snyder SC, Steele L, Stringfel-
low M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A,
Tran T, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC,
Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick MH,
Weber B, Kamb A, Goldgar DE: The complete BRCA2 gene and
mutations in chromosome 13q-linked kindreds. Nat Genet
1996, 12:333-337.
11. Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonas-
son JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjord JE:
A single BRCA2 mutation in male and female breast cancer
families from Iceland with varied cancer phenotypes. Nat
Genet 1996, 13:117-119.
12. Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonas-
son JG, Tryggvadottir L, Tulinius H, Eyfjord JE: Study of a single
BRCA2 mutation with high carrier frequency in a small popu-
lation. Am J Hum Genet 1997, 60:1079-1084.
13. Thorlacius S, Struewing JP, Hartge P, Olafsdottir GH, Sigvalda-
son H, Tryggvadottir L, Wacholder S, Tulinius H, Eyfjord JE: Pop-
ulation-based study of risk of breast cancer in carriers of
BRCA2 mutation. Lancet 1998, 352:1337-1339.
14. Losson R, Lacroute F: Interference of nonsense mutations with
eukaryotic messenger RNA stability. Proc Natl Acad Sci USA
1979, 76:5134-5137.
15. Schell T, Kulozik AE, Hentze MW: Integration of splicing, transport
and translation to achieve mRNA quality control by the non-
sense-mediated decay pathway [review]. Genome Biol 2002,
3:1006. [http://genomebiology.com/2002/3/3/reviews/1006]
16. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM: Cancer-
predisposing mutations within the RING domain of BRCA1:
loss of ubiquitin protein ligase activity and protection from
radiation hypersensitivity. Proc Natl Acad Sci USA 2001, 98:
5134-5139.
17. Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder BA,
Stratton MR, Easton D: Variation of risks of breast and ovarian
cancer associated with different germline mutations of the
BRCA2 gene. Nat Genet 1997, 15:103-105.
18. Mizuta R, LaSalle JM, Cheng HL, Shinohara A, Ogawa H,
Copeland N, Jenkins NA, Lalande M, Alt FW: RAB22 and
RAB163/mouse BRCA2: proteins that specifically interact
with the RAD51 protein. Proc Natl Acad Sci USA 1997, 94:
6927-6932.
19. Wong AK, Pero R, Ormonde PA, Tavtigian SV, Bartel PL: RAD51
interacts with the evolutionarily conserved BRC motifs in the
human breast cancer susceptibility gene brca2. J Biol Chem
1997, 272:31941-31944.
20. Gorlich D, Mattaj IW: Nucleocytoplasmic transport. Science
1996, 271:1513-1518.
21. Sarkisian CJ, Master SR, Huber LJ, Ha SI, Chodosh LA: Analysis
of murine Brca2 reveals conservation of protein–protein inter-
actions but differences in nuclear localization signals. J Biol
Chem 2001, 276:37640-37648.
Correspondence
Thorunn  Rafnar, Iceland Genomics Corporation, Snorrabraut 60,
105 Reykjavik, Iceland. Tel: +354 525 3600; fax: +354 525 3608;
e-mail: thorunnr@uvs.is
Breast Cancer Research    Vol 6 No 4 Mikaelsdottir et al.
R290